Drugs in the Treatment of Obesity: Sibutramine, Orlistat and Rimonabant

Public Health Nutrition - United Kingdom
doi 10.1017/s1368980007000717
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cambridge University Press (CUP)

Related search

Benefit-Risk Assessment of Orlistat in the Treatment of Obesity

Drug Safety
ToxicologyPharmacology
2014English

Combinations of Drugs in the Treatment of Obesity

Pharmaceuticals
Molecular MedicinePharmaceutical Science
2010English

Weight Reduction and Long-Term Maintenance After 18 Months Treatment With Orlistat for Obesity

International Journal of Obesity
NutritionEndocrinologyDieteticsMedicineMetabolismDiabetes
2003English

Comparison of the Central Action of Drugs for Medical Treatment of Obesity

Obesity and Metabolism
Internal MedicineNutritionEndocrinologyPublic HealthEnvironmentalDieteticsOccupational HealthMetabolismDiabetes
2014English

Melanotropins as Drugs for the Treatment of Obesity and Other Feeding Disorders: Potential and Problems

Current Topics in Medicinal Chemistry
MedicineDrug Discovery
2009English

Crystal Structure of Pathogenic Staphylococcus Aureus Lipase Complex With the Anti-Obesity Drug Orlistat

Scientific Reports
Multidisciplinary
2020English

A Common Variant in the Adiponectin Gene on Weight Loss and Body Composition Under Sibutramine Therapy in Obesity

Clinical Pharmacology: Advances and Applications
Pharmacology
2010English

FDA Approval of Obesity Drugs

JAMA - Journal of the American Medical Association
Medicine
2012English

Sibutramine and L-Carnitine Compared to Sibutramine Alone on Insulin Resistance in Diabetic Patients

Internal Medicine
Internal MedicineMedicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy